본문 바로가기
KERD
논문KCI 등재

Polycystic kidney disease and therapeutic approaches

박종훈|박은영|우유미
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2011.06|BMB Reports|제44권 제6호|pp. 359-368

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

miRNAPolycystic kidney diseaseHDAC inhibitorDrug developmentEpigenetic
주제분류화학

초록

Polycystic kidney disease (PKD) is a common genetic disorder in which extensive epithelial-lined cysts develop in the kidneys. In previous studies, abnormalities of polycystin protein and its interacting proteins, as well as primary cilia, have been suggested to play critical roles in the development of renal cysts. However, although several therapeutic targets for PKD have been suggested, no early diagnosis or effective treatments are currently available. Current developments are active for treatment of PKD including inhibitors or antagonists of PPAR-γ, TNF-α, CDK and VEGF. These drugs are potential therapeutic targets in PKD, and need to be determined about pathological functions in human PKD. It has recently been reported that the alteration of epigenetic regulation, as well as gene mutations, may affect the pathogenesis of PKD. In this review,we will discuss recent approaches to PKD therapy. It provides important information regarding potential targets for PKD. [BMB reports 2011; 44(6): 359-368]

Abstract

Polycystic kidney disease (PKD) is a common genetic disorder in which extensive epithelial-lined cysts develop in the kidneys. In previous studies, abnormalities of polycystin protein and its interacting proteins, as well as primary cilia, have been suggested to play critical roles in the development of renal cysts. However, although several therapeutic targets for PKD have been suggested, no early diagnosis or effective treatments are currently available. Current developments are active for treatment of PKD including inhibitors or antagonists of PPAR-γ, TNF-α, CDK and VEGF. These drugs are potential therapeutic targets in PKD, and need to be determined about pathological functions in human PKD. It has recently been reported that the alteration of epigenetic regulation, as well as gene mutations, may affect the pathogenesis of PKD. In this review,we will discuss recent approaches to PKD therapy. It provides important information regarding potential targets for PKD. [BMB reports 2011; 44(6): 359-368]

참고문헌 (106)

  1. Igarashi, P, "Genetics and pathogenesis of polycystic kidney disease", J. Am. Soc. Nephrol, 13, pp.2384~2398 (2002)
  2. Torres, V. E, "Autosomal dominant polycystic kidney disease: the last 3 years", Kidney Int, 76, pp.149~168 (2009)
  3. Watnick, T, "From cilia to cyst", Nat. Genet, 34, pp.355~356 (2003)
  4. Nauli, S. M, "Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells", Nat. Genet, 33, pp.129~137 (2003)
  5. Belibi, F. A, "Novel targets for the treatment of autosomal dominant polycystic kidney disease", Expert. Opin. Investig. Drugs, 19, pp.315~328 (2010)
  6. Shillingford, J. M, "The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease", Proc. Natl. Acad. Sci. U. S. A, 103, pp.5466~5471 (2006)
  7. Gao, X, "Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling", Nat. Cell Biol, 4, pp.699~704 (2002)
  8. Distefano, G, "Polycystin-1 regulates extracellular signal- regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1", Mol. Cell Biol, 29, pp.2359~2371 (2009)
  9. Zafar, I, "Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)", Nephrol. Dial Transplant, 246, pp.2349~2353 (2009)
  10. Yamaguchi, T, "Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells", J. Am. Soc. Nephrol, 17, pp.178~187 (2006)
  11. Yamaguchi, T, "Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells", Am. J. Physiol. Renal. Physiol, 299, pp.F944~F951 (2010)
  12. Sas, K. M, "Targeting B-Raf as a treatment strategy for polycystic kidney disease", Am. J Physiol. Renal. Physiol, 299, pp.F942~F943 (2010)
  13. Takiar, V, "Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis", Proc. Natl. Acad. Sci. U. S. A, 108, pp.2462~2467 (2011)
  14. Harris, P. C, "Polycystic kidney disease", Annu. Rev. Med, 60, pp.321~337 (2009)
  15. Taby, R, "Cancer epigenetics", Cancer J. Clin, 60, pp.376~392 (2010)
  16. Felsenfeld, G, "Controlling the double helix", Nature, 421, pp.448~453 (2003)
  17. Strahl, B. D, "The language of covalent histone modifications", Nature, 403, pp.41~45 (2000)
  18. Tsankova, N, "Epigenetic regulation in psychiatric disorders", Nat. Rev. Neurosci, 8, pp.355~367 (2007)
  19. Pasquinelli, A. E, "Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA", Nature, 408, pp.86~89 (2000)
  20. Filipowicz, W, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight", Nat. Rev. Genet, 9, pp.102~114 (2008)
  21. Lewis, B. P, "Prediction of mammalian microRNA targets", Cell, 115, pp.787~798 (2003)
  22. Friedman, R. C, "Most mammalian mRNAs are conserved targets of microRNAs", Genome Res, 19, pp.92~105 (2009)
  23. Calin, G. A, "MicroRNA signatures in human cancers", Nat. Rev. Cancer, 6, pp.857~866 (2006)
  24. Volinia, S, "A microRNA expression signature of human solid tumors defines cancer gene targets", Proc. Natl. Acad. Sci. U. S. A, 103, pp.225~2261 (2006)
  25. Kato, M, "MicroRNAs and their role in progressive kidney diseases", Clin. J. Am. Soc. Nephrol, 4, pp.1255~1266 (2009)
  26. Saal, S, "MicroRNAs and the kidney: coming of age", Curr. Opin. Nephrol. Hypertens, 18, pp.317~323 (2009)
  27. Li, X, "Epigenetics and autosomal dominant polycystic kidney disease", Biochim. Biophys. Acta (2010)
  28. Vasyutina, E, "Molecular mechanisms in renal degenerative disease", Semin. Cell Dev. Biol, 21, pp.831~837 (2010)
  29. Karolina, D. S, "Riboregulators in kidney development and function", Biochimie, 92, pp.217~225 (2010)
  30. Kliewer, S. A, "The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways", Recent Prog. Horm. Res, 54, pp.345~367 (1999)
  31. Liu, Y, "Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells", Basic Clin. Pharmacol. Toxicol, 106, pp.523~530 (2010)
  32. Muto, S, "Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant", Hum. Mol. Genet, 11, pp.1731~1742 (2002)
  33. Dai, B, "Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats", Clin. Sci, 119, pp.323~333 (2010)
  34. Raphael, K. L, "Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease", Am. J. Nephrol, 30, pp.468~473 (2009)
  35. Xu, N, "Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis", J. Nephrol, 19, pp.529~534 (2006)
  36. Guan, Y, "Peroxisome proliferator- activated receptors (PPARs): novel therapeutic targets in renal disease", Kidney Int, 60, pp.14~30 (2001)
  37. Liu, M, "DH9, a novel PPARgamma agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of beta-catenin signaling", Invest. New Drugs, 28, pp.783~790 (2010)
  38. Balkwill, F, "Tumour necrosis factor and cancer", Nat. Rev. Cancer, 9, pp.361~371 (2009)
  39. Gardner, K. D, "Cytokines in fluids from polycystic kidneys", Kidney Int, 39, pp.718~724 (1991)
  40. Merta, M, "Cytokine profile in autosomal dominant polycystic kidney disease", Biochem. Mol. Biol. Int, 41, pp.619~624 (1997)
  41. Li, X, "A tumor necrosis factor- alpha-mediated pathway promoting autosomal dominant polycystic kidney disease", Nat. Med, 146, pp.863~868 (2008)
  42. Pirson, Y, "Does TNF-alpha enhance cystogenesis in ADPKD", Nephrol. Dial Transplant, 23, pp.3773~3775 (2008)
  43. Bukanov, N. O, "Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine", Nature, 444, pp.949~952 (2006)
  44. McClue, S. J, "In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)", Int. J. Cancer, 102, pp.463~468 (2002)
  45. Park, J. Y, "Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease", Am. J. Nephrol, 29, pp.509~515 (2009)
  46. Ibraghimov-Beskrovnaya, O, "Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy", Cell Cycle, 6, pp.776~779 (2007)
  47. Moreno, S, "Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD", Cell Cycle, 70, pp.1856~1864 (2008)
  48. Bello-Reuss, E, "Angiogenesis in autosomal-dominant polycystic kidney disease", Kidney Int, 60, pp.37~45 (2001)
  49. Klagsbrun, M, "Molecular angiogenesis", Chem. Biol, 6, pp.R217~R224 (1999)
  50. Tao, Y, "VEGF receptor inhibition slows the progression of polycystic kidney disease", Kidney Int, 72, pp.1358~1366 (2007)
  51. Amura, C. R, "VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25", -) mice, 2007, pp.293, c419~c428
  52. McGrath-Morrow, S, "VEGF receptor 2 blockade leads to renal cyst formation in mice", Kidney Int, 69, pp.1741~1748 (2006)
  53. Bernhardt, W. M, "Involvement of hypoxia-inducible transcription factors in polycystic kidney disease", Am. J. Pathol, 170, pp.830~842 (2007)
  54. Gao, J, "Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways", Eur. J. Pharmacol, 654, pp.92~99 (2011)
  55. Leonhard, W. N, "Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model", Am. J. Physiol. Renal Physiol, 300, pp.F1193~F1202 (2011)
  56. Leuenroth, S. J, "Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease", Proc. Natl. Acad. Sci. U. S. A, 104, pp.4389~4394 (2007)
  57. Natoli, T. A, "Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models", Nat. Med, 16, pp.788~792 (2010)
  58. Chatterjee, S, "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease", J. Lipid Res, 37, pp.1334~1344 (1996)
  59. Yoo, C. B, "Epigenetic therapy of cancer: past, present and future", Nat. Rev. Drug Discov, 5, pp.37~50 (2006)
  60. Mutskov, V, "Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9", EMBO J, 23, pp.138~149 (2004)
  61. Taplick, J, "Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1", J. Mol. Biol, 308, pp.27~38 (2001)
  62. Taunton, J, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p", Science, 272, pp.408~411 (1996)
  63. Bertos, N. R, "Class II histone deacetylases: structure, function, and regulation", Biochem. Cell Biol, 79, pp.243~252 (2001)
  64. Deribe, Y. L, "Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6", Sci. Signal, 2, pp.ra84~ (2009)
  65. Valenzuela-Fernandez, A, "HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions", Trends Cell Biol, 183, pp.291~297 (2008)
  66. Bali, P, "Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors", J. Biol. Chem, 280, pp.26729~26734 (2005)
  67. Van Bodegom, D, "The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression", J. Biol. Chem, 281, pp.31234~31244 (2006)
  68. Cao, Y, "Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models", Proc. Natl. Acad. Sci. U. S. A, 106, pp.21819~21824 (2009)
  69. van Bodegom, D, "Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter", Biochim. Biophys. Acta, 1799, pp.502~509 (2010)
  70. Nishio, S, "Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation", J. Clin. Invest, 115, pp.910~918 (2005)
  71. McKinsey, T. A, "MEF2: a calcium-dependent regulator of cell division, differentiation and death", Trends Biochem. Sci, 27, pp.40~47 (2002)
  72. Xia, S, "Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts", Development, 137, pp.1075~1084 (2010)
  73. Pugacheva, E. N, "HEF1-dependent Aurora A activation induces disassembly of the primary cilium", Cell, 129, pp.1351~1363 (2007)
  74. Song, X, "Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks", Hum. Mol. Genet, 18, pp.2328~2343 (2009)
  75. Bieliauskas, A. V, "Isoform-selective histone deacetylase inhibitors", Chem. Soc. Rev, 37, pp.1402~1413 (2008)
  76. Mehnert, J. M, "Histone deacetylase inhibitors: biology and mechanism of action", Cancer J, 13, pp.23~29 (2007)
  77. Qian, F, "The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I", Cell, 87, pp.979~987 (1996)
  78. Ambros, V, "A uniform system for microRNA annotation", RNA, 9, pp.277~279 (2003)
  79. Kim,V.N, "MicroRNA biogenesis: coordinated cropping and dicing", Nat. Rev. Mol. Cell Biol, 6, pp.376~385 (2005)
  80. Gregory, R. I, "Human RISC couples microRNA biogenesis and posttranscriptional gene silencing", Cell, 123, pp.631~640 (2005)
  81. Tijsterman, M, "Dicers at RISC; the mechanism of RNAi", Cell, 117, pp.1~3 (2004)
  82. Rodriguez, A, "Identification of mammalian microRNA host genes and transcription units", Genome Res, 14, pp.1902~1910 (2004)
  83. Altuvia, Y, "Clustering and conservation patterns of human microRNAs", Nucleic Acids Res, 33, pp.2697~2706 (2005)
  84. Liang, M, "MicroRNA: a new frontier in kidney and blood pressure research", Am. J. Physiol. Renal Physiol, 297, pp.F553~F558 (2009)
  85. Landgraf, P, "A mammalian microRNA expression atlas based on small RNA library sequencing", Cell, 129, pp.1401~1414 (2007)
  86. Sun, Y, "Development of a micro- array to detect human and mouse microRNAs and characterization of expression in human organs", Nucleic Acids Res, 32, pp.e188~ (2004)
  87. Akkina, S, "MicroRNAs in kidney function and disease", Transl. Res, 157, pp.236~240 (2011)
  88. Razzaque, M. S, "Protooncogene Ets-1 and the kidney", Nephron, 89, pp.1~4 (2001)
  89. Lee, S. O, "MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease", J. Clin. Invest, 118, pp.3714~3724 (2008)
  90. Pandey, P, "Systems biology approach to identify transcriptome reprogramming and microRNA targets during the progression of Polycystic Kidney Disease", BMC. Syst. Biol, 5, pp.56~ (2011)
  91. Tan, Y. C, "Autosomal dominant polycystic kidney disease: Genetics, mutations and microRNAs", Biochim. Biophys. Acta (2011)
  92. Sun, H, "MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation", Mol. Biol. Rep, 37, pp.2951~2958 (2010)
  93. Tran, U, "The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity", Development, 137, pp.1107~1116 (2010)
  94. Chung, A. C, "miR-192 mediates TGF-beta", Smad3-driven renal fibrosis, 2010, pp.21, 1317~1325
  95. Kato, M, "MicroRNA-192 in di abetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors", Proc. Natl. Acad. Sci. U. S. A, 104, pp.3432~3437 (2007)
  96. Krupa, A, "Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy", J. Am. Soc. Nephrol, 21, pp.438~447 (2010)
  97. Gregory, P. A, "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1", Nat. Cell Biol, 10, pp.593~601 (2008)
  98. Korpal, M, "The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2", J. Biol. Chem, 283, pp.14910~14914 (2008)
  99. Bracken, C. P, "A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition", Cancer Res, 68, pp.7846~7854 (2008)
  100. Oba, S, "miR-200b precursor can ameliorate renal tubulointerstitial fibrosis", PLoS One, 5, pp.e13614~ (2010)
  101. Lu, J, "MicroRNA expression profiles classify human cancers", Nature, 435, pp.834~838 (2005)
  102. Bhatt, K, "microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles", Am. J. Physiol. Renal Physiol, 300, pp.F602~F610 (2011)
  103. Masyuk, A. I, "Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am. J. Physiol. Gastrointest", Liver Physiol, 299, pp.G990~G999 (2010)
  104. Masyuk, T, "MicroRNAs in cholangiociliopathies", Cell Cycle, 8, pp.1324~1328 (2009)
  105. Krutzfeldt, J, "Silencing of microRNAs in vivo with 'antagomirs'", Nature, 438, pp.685~689 (2005)
  106. Esau, C. C, "Therapeutic potential for microRNAs", Adv. Drug Deliv. Rev, 59, pp.101~114 (2007)

관련 논문AI추천

Mouse models of polycystic kidney disease induced by defects of ciliary proteins고제영, 박종훈생화학분자생물학회 · BMB Reports2013 · 제46권 제2호Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients박혜인, Hyunjin Ryu, Kook-Hwan Oh, Yong-Chul Kim, Yun Kyu Oh대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제4호Autosomal Dominant Polycystic Kidney Disease: 2009 Update for InternistsWilliam M. Bennett대한내과학회 · The Korean Journal of Internal Medicine2009 · 제24권 제3호CRISPR-Cas9 system in autosomal dominant polycystic kidney disease: a comprehensive reviewKang Seungyeon, Kronbichler Andreas, Lee Min Ho, Park Se Jin, Shin Jae Il대한소아신장학회 · Childhood Kidney Diseases2025 · 제29권 제1호Mxi1 influences cyst formation in three-dimensional cell culture고제영, 김보혜, 박종훈, 우유미, 유경현, 이은지, EunSun Chang, Min Ji Seo, Seon Ah Song, Yeon Joo Yook생화학분자생물학회 · BMB Reports2012 · 제45권 제3호Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease고제영, 김대원, 김도연, 박은영, 박정환, 박종훈, 박진서, 손오라, 신민재, 여은지, 여현지, 윤종규, 음원식, 이치헌, 조성우, 조수빈, 조효상, 최수영, 최연주생화학분자생물학회 · BMB Reports2017 · 제50권 제9호

이 간행물의 다른 논문 (9건)

Tmp21, a novel MHC-I interacting protein, preferentially binds to β2-microglobulin-free MHC-I heavy chainsYoungsoo Jun, 안광석pp. 369-374Carboxy-terminus truncations of Bacillus licheniformis SK-1 CHI72 with distinct substrate specificityRath Pichyangkura, Sanya Kudan, Kamontip Kuttiyawongpp. 375-380Human HS1BP3 induces cell apoptosis and activates AP-1Dalong Ma, Jieshi Xie, Taiping Shi, Feng Wang, Ying Xiong, Weiwei Deng, Jinhai Guopp. 381-386Characterization of the molecular features and expression patterns of two serine proteases in Hermetia illucens (Diptera: Stratiomyidae) larvae배성우, 한상미, 김아영, 고영호, 이상범, 최영철, 박관호, 김원태, 박영한pp. 387-392Exogenous JH and ecdysteroid applications alter initiation of polydnaviral replication in an endoparasitoid wasp, Cotesia plutellae (Braconidae: Hymenoptera)Bokri Park, 김용균pp. 393-398
원문 보기